Erlocip 150mg Tablet is a highly effective targeted anti-cancer medication containing Erlotinib 150 mg, manufactured by Cipla Ltd. This oral EGFR tyrosine kinase inhibitor (EGFR-TKI) is specifically designed for the treatment of non-small cell lung cancer (NSCLC) with confirmed EGFR mutations and certain advanced pancreatic cancers. Erlotinib blocks the signaling pathways promoting tumor cell growth and division by inhibiting the EGFR protein's tyrosine kinase activity, thereby slowing down or halting cancer progression. Erlocip 150mg is used as a first-line therapy for EGFR mutation-positive NSCLC, as maintenance therapy post-platinum chemotherapy, and for treatment following chemotherapy failure. Additionally, it is prescribed in combination with gemcitabine for locally advanced or metastatic pancreatic cancer. The tablet provides an oral targeted therapy option that substantially improves patient convenience by eliminating the need for intravenous administration and offers the potential to enhance survival and quality of life in patients with advanced cancers. The medication is available in blister packs of 30 tablets each and requires a strict oncologist's supervision for administration, with necessary monitoring of liver and kidney functions during treatment. Patients must adhere to dosing guidelines and avoid smoking to maximize therapeutic efficacy.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Erlotinib 150 mg |
| Therapeutic Class | EGFR Tyrosine Kinase Inhibitor (Targeted Therapy) |
| Indications | NSCLC with EGFR mutations, locally advanced/metastatic NSCLC post-chemotherapy, pancreatic cancer in combination with gemcitabine |
| Administration Route | Oral tablet |
| Dosage | 150 mg once daily (NSCLC); 100 mg once daily with gemcitabine (Pancreatic cancer) |
| Packaging | Blister pack of 30 tablets |
| Storage Conditions | Below 30°C, dry place, protected from light and moisture |
| Manufacturer | Cipla Ltd. |
| Side Effects | Rash, diarrhea, appetite loss, fatigue |
| Special Notes | Requires oncologist supervision; smoking reduces effectiveness |
| Attributes | Description |
|---|---|
| Generic Name | Erlotinib |
| Dosage Strength | 150 mg per tablet |
| Formulation | Tablet |
| Pharmacological Action | EGFR tyrosine kinase inhibitor that blocks cancer cell proliferation and induces apoptosis |
| Therapeutic Area | Oncology - Targeted Cancer Therapy |
| Indications | Non-Small Cell Lung Cancer, Pancreatic Cancer |
| Recommended Dose | 150 mg once daily for NSCLC, 100 mg daily with gemcitabine for pancreatic cancer |
| Route of Administration | Oral |
| Storage Instructions | Store below 30°C in dry place, protect from light and moisture |
| Manufacturer | Cipla Ltd. |
| Packaging Details | Box or blister pack containing 30 tablets |
| Contraindications | Pregnancy and breastfeeding |
| Monitoring Requirements | Liver and kidney function tests advised during therapy |
| Drug Interactions | Smoking reduces effectiveness; monitor patient status closely |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Yes, Erlocip 150mg is indicated as a first-line treatment for patients with non-small cell lung cancer (NSCLC) who have confirmed EGFR mutations.
For pancreatic cancer, Erlocip is administered at 100 mg once daily in combination with gemcitabine, differing from the 150 mg dosage used for NSCLC.
Yes, Erlocip tablets should be stored below 30°C in a dry place and protected from light and moisture to maintain stability.
Smoking has been shown to reduce the effectiveness of Erlocip; therefore, patients are advised to cease smoking during treatment.
Liver and kidney function should be closely monitored throughout treatment with Erlocip to detect any potential adverse effects.
Common side effects include rash, diarrhea, loss of appetite, and fatigue; patients should report any severe or persistent symptoms to their healthcare provider.
Country Of Origin: India
Product Name: Erlocip 150mg Tablet
Generic Name: Erlotinib 150 mg
Manufacturer:
Cipla Ltd.
Therapeutic Category:
Oncology / Targeted Therapy (EGFR Tyrosine Kinase Inhibitor)
Product Description:
Erlocip 150mg contains Erlotinib, a targeted anti-cancer medicine classified as an EGFR tyrosine kinase inhibitor (EGFR-TKI).
It is used for the treatment of certain lung cancers and pancreatic cancer, particularly in patients whose tumors have epidermal growth factor receptor (EGFR) mutations.
Erlotinib works by blocking signals from the EGFR protein that promote cancer cell growth and division, thereby slowing or stopping tumor progression.
Indications:
• Non-Small Cell Lung Cancer (NSCLC):
o First-line treatment in patients with EGFR mutations
o Maintenance therapy after platinum-based chemotherapy
o Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen
• Pancreatic Cancer:
o In combination with gemcitabine for locally advanced, unresectable, or metastatic disease
Mechanism of Action:
• Erlotinib selectively inhibits the tyrosine kinase activity of the EGFR receptor.
• Prevents phosphorylation and downstream signaling, leading to inhibition of cancer cell proliferation and induction of apoptosis.
Dosage & Administration:
• 150 mg once daily on an empty stomach (at least 1 hour before or 2 hours after meals).
• For pancreatic cancer: 100 mg once daily (with gemcitabine).
• Dose adjustments may be required based on tolerance and side effects.
Key Benefits:
• Oral targeted therapy – no hospital infusion required.
• Effective in EGFR mutation–positive lung cancers.
• Can improve survival and quality of life in advanced cancers.
Packaging:
• Box / Blister pack of 30 tablets (150 mg each).
Storage:
• Store below 30°C, in a dry place.
• Protect from light and moisture.
Important Notes:
• For use under strict oncologist supervision only.
• Common side effects: rash, diarrhea, loss of appetite, fatigue.
• Smoking reduces drug effectiveness – patients should stop smoking.
• Liver and kidney function should be monitored during treatment.
• Not recommended in pregnancy or breastfeeding.
Melizza Lifescience
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
